Addex Spin-Out Neurosterix has started a Phase 1 Clinical Study with M4 PAM - NTX-253 for Schizophrenia

Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, January 7, 2026 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a ...
Medscape

Positive Phase 3 Results for First-in-Class Parkinson's Med

PHILADELPHIA — Tavapadon, an experimental first-in-class oral selective partial D1/D5 dopamine receptor agonist for Parkinson's disease (PD), was shown to significantly reduce disease burden in two ...
Psychology Today

What’s the Deal With Dopamine and ADHD?

Why do some brains crave more stimulation than others? Learn about dopamine, genetics, and brain function, and how dopamine ...
Medscape

A Randomized, Double-Blind, Placebo-Controlled Trial of Pramipexole, a Dopamine Agonist, in Patients With Fibromyaglia Receiving Concomitant Medications

Arthritis & Rheumatism. 2005;52(8):2495-2505. The mechanism of fibromyalgia, a chronic illness characterized by muscle pain, fatigue, and sleep disturbances, is unknown and medications used to ...
Nasdaq

Alto Neuroscience Announces Acquisition of Novel Dopamine Agonist Combination Product Candidate, Adding Late-Stage Readout in Treatment Resistant Depression Within Current Cash ...

– ALTO-207 (fka CTC-501) is a fixed-dose combination of pramipexole and ondansetron designed to induce rapid antidepressant effects while mitigating dose-limiting adverse events of pramipexole – – ...

Scientists Say a Major Assumption About Parkinson’s Disease May Be Wrong

Researchers at McGill University have uncovered a surprising twist in how dopamine affects movement, overturning a ...